Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

8 results
10:14 PM, Mar 30, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

CHS-1420: Ph I CHS-1420-03 data

12 (see BioCentury, Aug. 15, 2016 ). Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif.  Product: Biosimilar adalimumab
6:12 PM, Feb 22, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

PF-06410293: Ph III REFLECTIONS B538-02 data

12. AbbVie Inc. (NYSE:ABBV; Chicago Ill.) markets Humira. Pfizer Inc. (NYSE:PFE), New York, N.Y.  Product: Biosimilar adalimumab
1:33 PM, Jan 20, 2017  |  BC Week In Review | Clinical News  |  Clinical Results

BI 695501: Ph III data

BI 695501 or when it expects regulatory decisions. Boehringer Ingelheim GmbH , Ingelheim, Germany  Product: Biosimilar adalimumab
8:44 AM, Dec 02, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

M923: Ph III data

Inc. in June (see BioCentury, Oct. 3 ). Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass.  Product: Biosimilar adalimumab
12:00 AM, Oct 24, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Biosimilar adalimumab: Phase III data

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan  Fujifilm Holdings Corp. (Tokyo:4901), Tokyo, Japan  Product: Biosimilar adalimumab
12:00 AM, Aug 15, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Biosimilar adalimumab: Phase III data

May 2017 (see BioCentury, May 23). Coherus BioSciences Inc. (NASDAQ:CHRS), Redwood City, Calif.   Product: Biosimilar adalimumab
12:00 AM, Jun 20, 2016  |  BC Week In Review | Clinical News  |  Clinical Results

Biosimilar adalimumab: Additional Phase III data

rates at week 24 (see BioCentury, July 13, 2015 & Nov. 23, 2015).   Product: Biosimilar adalimumab
12:00 AM, Feb 16, 2015  |  BC Week In Review | Clinical News  |  Clinical Results

Biosimilar adalimumab: Phase I data

Inc. , Cranbury, N.J.   Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521), Zhejiang, China   Product: Biosimilar adalimumab